RedX Pharma CEO focuses on pipeline that found Lilly’s rising starBack in 2017, the UK biotech RedX Pharma had to sell its prized asset after administrators stepped in Share XRedX Pharma CEO focuses on pipeline that found Lilly’s rising starhttps://pharmaphorum.com/news/redx-looks-to-keep-pipeline-assets-after/
AI health record scanning could identify pancreatic cancer earlyArtificial intelligence (AI) could hold the key to identifying people at risk of pancreatic cancer early, allowing them Share XAI health record scanning could identify pancreatic cancer earlyhttps://pharmaphorum.com/news/ai-health-record-scanning-could-identify-pancreatic-cancer-early/
‘More people will die from pancreatic cancer’: How COVID-19 is diverting resources and costing livesMore people with pancreatic cancer will die from the disease if the COVID-19 crisis continues to demand the Share X‘More people will die from pancreatic cancer’: How COVID-19 is diverting resources and costing liveshttps://pharmaphorum.com/views-analysis-oncology/more-people-will-die-from-pancreatic-cancer-how-covid-19-is-diverting-resources-and-costing-lives/
AZ, Merck add pancreatic cancer to Lynparza’s growing use listAstraZeneca and Merck & Co have cemented their lead in the PARP inhibitor class with FDA approval for Share XAZ, Merck add pancreatic cancer to Lynparza’s growing use listhttps://pharmaphorum.com/news/az-merck-add-pancreatic-cancer-to-lynparzas-growing-use-list/
AZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerAstraZeneca and Merck & Co are closer to a new use for their PARP inhibitor Lynparza in pancreatic Share XAZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerhttps://pharmaphorum.com/news/azs-lynparza-inches-towards-game-changer-okay-in-pancreatic-cancer/
Halozyme abandons cancer R&D as lead drug failedUS biotech Halozyme has been forced to cut more than half its workforce and exit cancer R&D after Share XHalozyme abandons cancer R&D as lead drug failedhttps://pharmaphorum.com/news/halozyme-abandons-cancer-rd-as-lead-drug-failed/
Lilly’s $1.6bn cancer drug draws blank in pancreatic cancer trialEli Lilly is looking at other uses for its new cancer immunotherapy pegilodecakin after it flopped in a Share XLilly’s $1.6bn cancer drug draws blank in pancreatic cancer trialhttps://pharmaphorum.com/news/lillys-1-6bn-cancer-drug-draws-blank-in-pancreatic-cancer-trial/
AZ/Merck & Co wow ASCO with pancreatic cancer dataFinding targeted therapies for pancreatic cancer has long been an issue for pharma, meaning that for decades the Share XAZ/Merck & Co wow ASCO with pancreatic cancer datahttps://pharmaphorum.com/news/az-merck-co-wow-asco-with-pancreatic-cancer-data/
Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and moreAZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, Share XOncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and morehttps://pharmaphorum.com/views-and-analysis/oncology-round-up-az-and-daiichi-score-key-trial-win-with-breast-cancer-antibody-and-more/
